Announcements Trials
Browse Landscape

Phase

Phase 1/2 1

Status

Completed 1

Sponsor Class

OTHER 1

Study Type

Interventional 1

Sponsor

Cancer Type

Other hematologic neoplasm 1

Conditions

Myelodysplastic Syndromes 7Leukemia, Myeloid, Acute 7Leukemia 7Multiple Myeloma 6Lymphoma 6Lymphoma, Non-Hodgkin 5Precursor Cell Lymphoblastic Leukemia-Lymphoma 4Leukemia, Myelogenous, Chronic, BCR-ABL Positive 4Leukemia, Lymphocytic, Chronic, B-Cell 3Hematologic Neoplasms 3Myeloproliferative Disorders 2Lymphoma, Large B-Cell, Diffuse 2Lymphoma, Follicular 2Leukemia, Myeloid, Accelerated Phase 2Hodgkin Disease 2Blast Crisis 2Thrombocythemia, Essential 1Primary Myelofibrosis 1Preleukemia 1Polycythemia Vera 1Paraproteinemias 1Non-Malignant Neoplasm 1Neoplasms, Plasma Cell 1Lymphoproliferative Disorders 1Lymphoma, Mantle-Cell 1Lymphoma, B-Cell, Marginal Zone 1Lymphoma, B-Cell 1Leukemia, Myelomonocytic, Juvenile 1Leukemia, Myelomonocytic, Chronic 1Leukemia, Biphenotypic, Acute 1

Interventions

ruxolitinib 1filanesib 1Stem Cell Transplantation 1Melphalan 1Clofarabine 1CPI-0610 1Alemtuzumab 1

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

1 trials
RecentStart dateEnrollment
Phase 1/2 × Preleukemia × Stem Cell Transplantation × Clear all
NCT00943592 2014-02-27

Clofarabine-Melphalan-Alemtuzumab Conditioning in Patients With Advanced Hematologic Malignancies

University of Chicago

Phase 1/2 Completed
82 enrolled 12 charts
Other hematologic neoplasm

Leukemia, Preleukemia

Data powered by HemOnc (CC BY 4.0) Colophon âš¡